Management of Agitation in Hepatic Encephalopathy

Clinical Context and Recommendations

The American Association for the Study of Liver Diseases recommends avoiding sedation whenever possible in patients with hepatic encephalopathy, as sedatives can precipitate or worsen the neurological state 1
The management of agitation in hepatic encephalopathy should prioritize non-pharmacological measures, such as a quiet environment, physical restraint if necessary, and minimization of stimuli, before considering pharmacological interventions 1

Benzodiazepines should be avoided in patients with hepatic encephalopathy due to their deleterious effects and prolonged clearance in liver failure 2
Haloperidol is a safer option than benzodiazepines for managing agitation in patients with liver disease, according to the Society of Critical Care Medicine 3

In acute liver failure, benzodiazepines with short action may be used in small doses to manage unmanageable agitation, but this is a limited exception to the general recommendation to avoid benzodiazepines in hepatic encephalopathy 1
The use of benzodiazepines should be limited to controlling seizures, and only in minimal doses of short-acting agents, due to their prolonged half-life in liver failure 2

Sedatives should not be used to manage agitation without first addressing underlying precipitating factors of encephalopathy, as recommended by the American College of Gastroenterology 2
Metoclopramide and other psychotropics should be avoided as they can precipitate or worsen encephalopathy 2